BIOTRANSPLANT FOR CELLULAR THERAPY BASED ON MESENCHYMAL BONE MARROW STEM CELLS

摘要

The invention relates to bioengineering and biopharmacology, in particular to obtaining a culture of human mesenchymal bone marrow stem cells used for producing a biotransplant. Said invention can be used in a cellular therapy, in particular for treating patients exhibiting the expressed mental retardation and significant cerebral morphological changes. A homogeneous population of mesenchymal stem cells (MSC) characterised according to cell markers CD 44+, CD 90+, CD105+, CD106+, CD45- AND CD 34- is separated. The homogeneous cells are obtainable at a media interface by centrifuging a heparanized bone marrow and are passed, not more than three times, on mattresses for producing a cell biomass. The thus obtained cell population is used for producing a biotransplant. The biotransplant based on the patient's own MSC in the 10% autoserum of the blood thereof is used for treating intellectually-mnestic diseases of different aetiology and for treating the pathological changes of cerebral tissue relating to a head and brain injury or to acute changes of cerebral circulation. The treatment is carried out by the parenchymatous or intravascular injection of a therapeutically effective amount of the biotransplant. Said invention makes it possible to obtain the biotransplant based on the homogeneous according to genetic markers cells without additional costs and as soon as possible.